Skip to main content
SpringerLink
Log in

Seit Mai 2019 Kassenleistung

Der neue Zoster-Totimpfstoff: Wen, wann, wie impfen?

The adjuvanted inactivated zoster vaccine

  • FORTBILDUNG . SCHWERPUNKT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Seit Dezember 2018 empfiehlt die STIKO den adjuvantierten Zoster-Totimpfstoff als Standard- und Indikationsimpfung, und seit Mai 2019 sind die gesetzlichen Kassen zur Kostenübernahme verpflichtet. Praxisrelevante Fragen und Antworten zum neuen Impfstoff finden Sie hier.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Ultsch B, Weidemann F, Koch J and Siedler A. Projektbericht - Modellierung von epidemiologischen und gesundheitsökonomischen Effekten von Impfungen zur Pravention von Herpes zoster. Verfügbar unter https://www.rki.de/DE/Content/Infekt/Impfen/ImpfungenAZ/Zoster/Modellierung_Zoster_Impfung.pdf. Robert Koch-Institut 2017

  2. Robert Koch-Institut. Empfehlungen der Standigen Impfkommission (STIKO) am Robert Koch-Institut - 2017/2018. Epid Bull 2017;34:333–380

    Google Scholar 

  3. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015;372:2087–96

    Article  PubMed  Google Scholar 

  4. Cunningham AL, Lal H, Kovac M, et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med 2016;375:1019–32

    Article  CAS  PubMed  Google Scholar 

  5. Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep 2018;67:103–108

    Article  PubMed  PubMed Central  Google Scholar 

  6. Warrington R, Ismail S and National Advisory Committee on Immunization. Summary of the NACI Update on Herpes Zoster Vaccines. Can Commun Dis Rep 2018;44:220–225

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Robert Koch-Institut. Mitteilung der Ständigen Impfkommission (STIKO) am RKI: Wissenschaftliche Begründung zur Empfehlung einer Impfung mit dem Herpes zoster-subunit-Totimpfstoff. Epid Bull 2018;50:541–567

    Google Scholar 

  8. Pauksens K, Volpe S, Schwarz TF, et al. Persistence of Immune Response to an Adjuvanted Varicella-Zoster Virus Subunit Candidate Vaccine for up to Year 9 in Older Adults. Open Forum Infectious Diseases 2017;4:S415–S415

    Article  PubMed Central  Google Scholar 

  9. Schwarz TF, Volpe S, Catteau G, et al. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccin Immunother 2018;14:1370–1377

    Article  PubMed  PubMed Central  Google Scholar 

  10. Didierlaurent AM, Laupeze B, Di Pasquale A, Hergli N, Collignon C and Garcon N. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines 2017;16:55–63

    Article  CAS  PubMed  Google Scholar 

  11. Grupping K, Campora L, Douha M, et al. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine. J Infect Dis 2017;216:1343–1351

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Berkowitz EM, Moyle G, Stellbrink HJ, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis 2015;211:1279–87

    Article  CAS  PubMed  Google Scholar 

  13. Oostvogels L. Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults with Hematologic Malignancies: A Phase III, Randomized Clinical Trial. Open Forum Infectious Diseases 2017;4:S415–S415

    Article  PubMed Central  Google Scholar 

  14. Vink P, Ramon Torrell JM, Sanchez Fructuoso A, et al. Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: a Phase III, Randomized Clinical Trial. Clin Infect Dis 2019

    Google Scholar 

  15. Winston DJ, Mullane KM, Cornely OA, et al. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2018;391:2116–2127

    Article  PubMed  Google Scholar 

  16. Eberhardson M, Hall S, Papp KA, et al. Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Clin Infect Dis 2017;65:1174–1182

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sektion Klinische Infektiologie, Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität, Ludwig-Maximilians-Universität München, Pettenkoferstr. 8a, D-80336, München, Deutschland

    Ulrich Seybold MSc

Authors
  1. Ulrich Seybold MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich Seybold MSc.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seybold, U. Der neue Zoster-Totimpfstoff: Wen, wann, wie impfen?. MMW - Fortschritte der Medizin 161, 33–36 (2019). https://doi.org/10.1007/s15006-019-0844-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-019-0844-6

Keywords

Search

Navigation